{"analyses":[{"ciLowerLimit":"1.0","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.87","groupDescription":"CR in the acute phase was to be tested using the same 2 sided CMH test as for the primary endpoint. netupitant/palonosetron combination was to be considered superior to palonosetron in the acute phase if the 2 sided p value from the CMH was less than or equal to 0.050 and in the right direction.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.047","pValueComment":"If the null hypothesis for CR delayed was rejected, analysis of the first key secondary endpoint CR acute was to be performed. Since the analysis was performed according to a hierarchical procedure, no further adjustment for multiplicity was needed.","paramType":"Odds Ratio (OR)","paramValue":"1.37","statisticalComment":"Cochran Mantel Haenszel (CMH) test including treatment, age class and region as strata. All missing data were to be imputed as treatment failures.","statisticalMethod":"Cochran-Mantel-Haenszel","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"85.9","upperLimit":"90.5","value":"88.4"},{"groupId":"OG001","lowerLimit":"82.2","upperLimit":"87.4","value":"85.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"724"},{"groupId":"OG001","value":"725"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule with oral dexamethasone, both given on Day 1, prior to each scheduled chemotherapy cycle\n\nNetupitant and Palonosetron\n\nDexamethasone","id":"OG000","title":"Netupitant and Palonosetron Plus Dexamethasone"},{"description":"Oral palonosetron 0.50 mg (Aloxi) with oral dexamethasone both given on Day 1, prior to each scheduled chemotherapy cycle\n\nPalonosetron\n\nDexamethasone","id":"OG001","title":"Palonosetron Plus Dexamethasone"}],"paramType":"NUMBER","populationDescription":"FAS","reportingStatus":"POSTED","timeFrame":"0-24 hours","title":"Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication at Cycle 1","type":"SECONDARY","unitOfMeasure":"percentage of responders"}